They may appeal to different kinds of investors.

Novo Nordisk is reportedly set to partner with telehealth firm Hims & Hers to sell its weight-loss drugs on the platform.

Novo’s CagriSema shot was shown to be less effective than rival Lilly’s tirzepatide ...

Novo Nordisk stock fell over 16% Monday after it said its next-generation weight loss drug didn't meet its primary target.

Novo Nordisk is losing to Eli Lilly in the fiercely competitive weight loss market. But one of the company's mid-stage assets could help it remain a key player.

It’s been a topsy-turvy week for Novo Nordisk, makers of the popular weight loss drugs Ozempic and Wegovy. Fresh off the heels of a disappointing trial for one experimental drug, the company has just ...

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and ...

New combo drug from Novo Nordisk leads to more weight loss than semaglutide alone, according to late-stage trial findings. Image credit: Kristian Tuxen Ladegaard Berg/NurPhoto via Getty Images GLP-1 ...

The Danish drugmaker’s latest trial setback intensifies its high-stakes rivalry with Eli Lilly in the booming obesity market.

The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures.

COPENHAGEN, Feb 24 (Reuters) - Novo Nordisk and United Laboratories International said on Tuesday a Chinese mid-stage trial ...